Authors
Abduladheem Al-Attabi, Mohammed Kassim Mohammed, Nada Khazal K Hindi
Published in
In vitro models. Volume 5. Issue 4. Pages 893-905. Epub Sep 28, 2026.
Abstract
Conventional two-dimensional cell lines and animal models each present well-recognized limitations for studying human viral infection: monolayer cultures lack tissue-level architecture and cellular heterogeneity, while species differences in receptor expression and immune physiology limit the translatability of animal data to human disease. Three-dimensional in vitro models, including air-liquid interface (ALI) transwell cultures, adult stem cell- and pluripotent stem cell-derived organoids, and microfluidic organ-on-chip platforms, have emerged as physiologically relevant alternatives that better recapitulate human tissue architecture, cellular diversity, and host-pathogen interactions. This review examines the application of these three-dimensional platforms across six domains of human viral pathogenesis: respiratory viruses (influenza, SARS-CoV-2, rhinovirus, respiratory syncytial virus) studied using ALI airway cultures, airway/lung/nasal organoids, and alveolar-capillary organ-on-chip systems; hepatotropic viruses (hepatitis B and C viruses) studied using perfused microfluidic liver cultures and patient-derived liver organoids capable of supporting complete viral replication cycles; enteric viruses (rotavirus, norovirus, coxsackievirus) studied using human intestinal enteroids and gut-on-chip systems; hemorrhagic-fever viruses (Ebola, Lassa) studied using microvessel-on-chip platforms; cardiotropic SARS-CoV-2 infection studied using engineered heart tissue; and neurotropic TORCH viruses (Toxoplasma, Other agents, Rubella, Cytomegalovirus, Herpes simplex virus - here represented by Zika virus and herpes simplex virus 1) studied using human brain organoids that recapitulate virus-induced microcephaly phenotypes. We compare the architecture, quantitative performance, strengths, and limitations of twenty-one representative platforms, position six platform classes on a physiological-relevance-versus-throughput landscape, summarize demonstrated applications in antiviral drug screening (including chip-based identification of amodiaquine and nafamostat repurposing candidates and a clinically important hydroxychloroquine false-positive), and extend the discussion to the translational challenges of donor variability, cross-laboratory standardization, throughput, and immune-cell integration that currently limit broader adoption of these models in preclinical virology and drug discovery pipelines.
PMID:
43034355
Bibliographic data and abstract were imported from PubMed on 15 Nov 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 6
- Comments 0